You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

metronomic capecitabine

Showing 1 - 25 of 1,464
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally

Recruiting
  • to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma
  • Capecitabine 500Mg Oral Tablet
  • Shanghai, China
    Eye & ENT Hospital, Fudan University
Jul 2, 2023

Nasopharyngeal Carcinoma Trial in Singapore (CCRT with Maintenance Tislelizumab and Metronomic Capecitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • CCRT with Maintenance Tislelizumab and Metronomic Capecitabine
  • Singapore, Singapore
  • +1 more
Oct 16, 2023

Metastatic Pancreatic Cancer Trial in Singapore (Low Dose OXIRI (LD-OXIRI))

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Low Dose OXIRI (LD-OXIRI)
  • Singapore, Singapore
    National Cancer Centre, Singapore
Jun 29, 2023

Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)

Active, not recruiting
  • Breast Cancer
  • Guangzhou, Guangdong, China
    State Key Laboratory of Oncology in South China, Sun Yat-sen Uni
Jan 27, 2023

Triple Negative Breast Cancer Trial in Guangzhou (Capecitabine, Tucidinostat)

Recruiting
  • Triple Negative Breast Cancer
  • Guangzhou, Guangdong, China
    Sun-yat sen university cancer center
Nov 1, 2022

Breast Cancer Trial in Guangzhou (Tucidinostat, Capecitabine, Endocrine Therapy)

Recruiting
  • Breast Cancer
  • Guangzhou, Gangdong, China
    Shusen Wang
Nov 1, 2022

Breast Cancer Trial in Zhengzhou (Capecitabine+endocrine therapy, Placebo+endocrine therapy)

Recruiting
  • Breast Cancer
  • Capecitabine+endocrine therapy
  • Placebo+endocrine therapy
  • Zhengzhou, Henan, China
    Henan cancer hospital
Nov 19, 2022

Breast Tumors, Locally Advanced or Metastatic Breast Cancer Trial in Guangzhou (Taxane plus Intermittent Capecitabine, Utidelone

Not yet recruiting
  • Breast Neoplasms
  • Locally Advanced or Metastatic Breast Cancer
  • Taxane plus Intermittent Capecitabine
  • +3 more
  • Guangzhou, Guangdong, China
    Shusen Wang
Dec 27, 2021

Nasopharyngeal Carcinoma Trial in Guangzhou (PD-1 antibody, Capecitabine)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 17, 2022

Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) Trial in Shanghai (Capecitabine,

Recruiting
  • Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)
  • Capecitabine, Camrelizumab
  • Shanghai, China
    Department of Oncology, Ruijin Hospital
Sep 16, 2021

Colo-rectal Cancer, Metastatic Cancer Trial in Besançon, Dijon, Montbéliard (Regorafenib, Cyclophosphamide, Capecitabine)

Active, not recruiting
  • Colo-rectal Cancer
  • Metastatic Cancer
  • Besançon, France
  • +2 more
Jan 24, 2023

Breast Cancer Trial in Beijing (oral vinorelbine and capecitabine)

Recruiting
  • Breast Cancer
  • oral vinorelbine and capecitabine
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Feb 27, 2023

Metastasis Breast Trial (letrozole)

Not yet recruiting
  • Metastasis Breast
  • (no location specified)
Jun 20, 2021

Head and Neck Squamous Cell Carcinoma Trial in Guangzhou (Capecitabine)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 15, 2022

Advanced Cervical Cancer Trial in Shanghai (Capecitabine, camrelizumab)

Recruiting
  • Advanced Cervical Cancer
  • Capecitabine, camrelizumab
  • Shanghai, China
    Department of Oncology, Ruijin Hospital
Jan 27, 2021

Metastatic Colorectal Cancer Trial in France (other, procedure, drug)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • quality of life questionnaires
  • +6 more
  • Besançon, France
  • +6 more
Jul 15, 2022

Neuroendocrine Tumors, Gastro Entero Pancreatic Neuroendocrine Tumors Trial in Meldola, Milan (28 GBq 177Lu-DOTATATE, 22 GBq

Active, not recruiting
  • Neuroendocrine Tumors
  • Gastro Entero Pancreatic Neuroendocrine Tumors
  • 28 GBq 177Lu-DOTATATE
  • 22 GBq 177Lu-DOTATATE
  • Meldola, FC, Italy
  • +1 more
Feb 25, 2021

Childhood Solid Tumor Trial in Belgium, France (Vinblastine, Cyclophosphamide, Capecitabine)

Recruiting
  • Childhood Solid Tumor
  • Brussel, Belgium
  • +10 more
May 27, 2022

HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer Trial in Los Angeles (drug, biological, other)

Terminated
  • HER2-positive Breast Cancer
  • +2 more
  • Los Angeles, California
    USC Norris Comprehensive Cancer Center
Aug 22, 2021

Metastatic Breast Cancer Trial in Beijing (Vinorelbine 40mg, Toripalimab 240mg, Bevacizumab 5 mg/kg)

Recruiting
  • Metastatic Breast Cancer
  • Vinorelbine 40mg
  • +5 more
  • Beijing, Beijing, China
  • +1 more
Feb 9, 2022

Pancreatic Cancer Trial in Shanghai (Capecitabine)

Recruiting
  • Pancreatic Cancer
  • Shanghai, China
    Department of Oncology, Ruijin Hospital
Apr 29, 2021

Breast Cancer, Estrogen Receptor-positive Breast Cancer, Metastatic Breast Cancer Trial in Cairo (Capecitabine, Letrozole 2.5mg)

Unknown status
  • Breast Cancer
  • +2 more
  • Cairo, Egypt
    Faculty of Medicine, Cairo University
Sep 25, 2020

Breast Cancer Trial in Italy (Paclitaxel, Cyclophosphamide, Capecitabine)

Active, not recruiting
  • Breast Cancer
  • Aviano, Italy
  • +19 more
Aug 31, 2022

Head Neck Cancer, Esophageal Squamous Cancer Trial in Shanghai (Capecitabine, Camrelizumab)

Recruiting
  • Head and Neck Cancer
  • Esophageal Squamous Cancer
  • Capecitabine, Camrelizumab
  • Shanghai, China
    Department of Oncology, Ruijin Hospital
Aug 12, 2020

Clinical Response, Toxicity, Survival Trial (metronomic XELOX, Classic XELOX, Blood samples for pharmacological studies)

Completed
  • Clinical Response
  • +2 more
  • metronomic XELOX
  • +2 more
  • (no location specified)
Jun 6, 2020